It is unknown whether a subset of patients with autoantibodies present early in the course of disease will go on to develop CTD autoantibody–associated clinical manifestations such as myositis (e.g., anti-SRP54) or thyroiditis (anti-TPO). This evidence concerns the gene TPO and thyroiditis.